Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Yamashita, Toshinari; Masuda, Norikazu; Saji, Shigehira; Araki, Kazuhiro; Ito, Yoshinori; Takano, Toshimi; Takahashi, Masato; Tsurutani, Junji; Koizumi, Kei; Kitada, Masahiro; Kojima, Yasuyuki; Sagara, Yasuaki; Tada, Hiroshi; Iwasa, Tsutomu; Kadoya, Takayuki; Iwatani, Tsuguo; Hasegawa, Hiroki; Morita, Satoshi; Ohno, Shinji

doi:10.1186/s13063-020-04341-y

Trials

Article metrics
Last updated: Fri, 19 Apr 2024 17:47:17 Z

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Access & Citations

3931

Article Accesses
7

Web of Science
7

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com